FDA Approves New Herceptin Biosimilar for the Treatment of Multiple HER2-Overexpressing Cancers

Hercessi marks Accord BioPharma’s first biosimilar to be approved in the United States, with multiple indications for HER2-overexpressing breast and gastric cancers.